San Francisco-based Thunderbolt — the first company established by Vitesse Biologics — has attained the rights to Astellas Pharma’s BAFF/APRIL dual antagonist program — a therapeutic solution developed for systemic lupus erythematosus (SLE) as well as a range of B-cell disorders, according to a recent announcement from Baxalta,…
News
The Alliance for Children’s Therapeutics presented positive results from an early study of KPI Therapeutics/Kineta’s lead drug candidate, dalazatide, as a possible treatment for children and teenagers with lupus nephritis. The data were given at the recent European League Against Rheumatism’s 17th Annual Congress in London. A key finding was that “patients with…
Researchers at New York University School of Medicine discovered that an enzyme’s failure to digest the DNA from dying cells can trigger the production of the auto-antibodies that are the hallmark of systemic lupus erythematosus (SLE). The findings were published in Cell, in a study titled “Digestion of Chromatin in…
Ten marker genes related to systemic lupus erythematosus (SLE) were identified from three different types of blood samples. These genes may have the potential to be used as biomarkers to diagnose or even predict SLE. They could also be used as therapeutic markers to measure how well SLE patients respond to treatment.
Mallinckrodt PLC presented the first results from its two-part pilot study’s 44-week open label extension period, on the efficacy of H.P. Acthar Gel, a repository corticotropin injection, in persistent systemic lupus erythematosus (SLE). Acthar is approved by the U.S. Food and Drug Administration for flares, or for maintenance therapy, in…
Genes regulating the growth factor VEGF signaling pathway are linked to the presence of mouth ulcers in people with systemic lupus erythematosus (SLE), according to a study presented at the European League Against Rheumatism Annual Congress (EULAR 2016) in London on June 10. The finding gives scientists a clue…
An associated risk between lupus and cervical cancer has recently been confirmed in a study titled “Cervical dysplasia and cervical cancer in women with rheumatoid arthritis,” presented at the EULAR Congress 2016 June 8-11 in London. Known as systemic lupus erythematosus or SLE, lupus is a condition characterized by chronic autoimmune…
ImmuPharma, a specialized drug discovery and development pharmaceutical company, announced its Phase 3 clinical trial of Lupuzor (rigerimod), the company’s lead potential breakthrough lupus treatment candidate, has made progress and has begun dosing its first European patients. In its update, ImmunoPharma said the Lupuzor Phase 3 study will enroll…
Researchers at Sun Yat-sen University in China have found that a group of anti-nuclear antibodies that target double stranded DNA, anti-dsDNA, may cause inflammation in systemic lupus erythomatosus (SLE) patients, through the activation of a particular molecular inflammasome. The findings were revealed in the study “Anti-dsDNA antibodies bind to TLR4…
Four key Lupus advocacy groups will host a Lupus Patient-Focused Drug Development Meeting next spring called “Lupus: Patient Voices,” according to a news release. The groups, the Alliance for Lupus Research (ALR), the Lupus Research Institute (LRI), the Lupus and Allied Diseases Association (LADA), and the Lupus Foundation of America (LFA), will lead the…
Recent Posts
- Galápagos’ oral therapy for lupus fails to meet key trial objective
- What I learned about navigating travel anxiety with lupus
- To my ‘forever nurse,’ who finally gave me my diagnosis of lupus
- New analyses show Benlysta may aid flare control, kidney health
- Can art therapy help lupus patients improve cognitive function?